<p>, /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO)（&#34;Dario&#34;或&#34;公司&#34;），全球数字健康市场的领导者，今天宣布进行一项私人配售，出售 2,713,180 股普通股（或相应的普通股等价物），每股价格为 6.45 美元，预计总收益约为 1750 万美元，未扣除发行费用。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="400" height="351" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg"/></p>
<p>此次发行的交割预计将在 2025 年 9 月 23 日左右进行，具体取决于常规交割条件的满足。公司计划将此次发行的净收益用于一般企业用途。</p>
<p>此次发行是基于《1933 年证券法》第 4(a)(2) 条款的注册要求豁免进行的（经修订的&#34;证券法&#34;），和/或根据其下发布的 D 条款，以及适用的州证券法。因此，私人配售中提供的证券不得在美国提供或出售，除非根据有效的注册声明或适用的注册要求豁免。公司已同意向证券交易委员会（&#34;SEC&#34;）提交注册声明，注册私人配售中出售的普通股的转售。</p>
<p>本新闻稿不构成出售这些证券的要约或购买这些证券的要约邀请，也不应在任何州或其他司法管辖区进行这些证券的出售，除非在任何此类州或其他司法管辖区的证券法下注册或资格之前进行的要约、邀请或出售是合法的。</p>
<p><strong>关于 DarioHealth Corp.</strong></p>
<p>DarioHealth Corp.（NASDAQ: DRIO）是一家领先的数字健康公司，通过以用户为中心的多慢性病数字治疗平台，彻底改变慢性病患者管理健康的方式。我们的平台和解决方案组合提供个性化和动态的干预措施，基于数据分析和一对一的指导，涵盖糖尿病、高血压、体重管理、肌肉骨骼疼痛和行为健康。</p>
<p>我们的以用户为中心的平台为人们提供持续和定制的健康护理，颠覆了传统的偶发医疗保健方式。这种方法使人们能够全面调整他们的生活方式，以实现可持续的行为改变，从而推动卓越的用户满意度、留存率和结果，使正确的选择变得容易。</p>
<p>Dario 在全球范围内向健康计划和其他支付方、自保雇主、护理提供者和消费者提供其高度用户评价的解决方案。要了解更多关于 Dario 及其数字健康解决方案的信息，请访问 http://dariohealth.com。</p>
<p><strong>关于前瞻性声明的警示说明</strong> 本新闻稿及公司代表和合作伙伴相关的声明包含或可能包含 1995 年《私人证券诉讼改革法》意义上的前瞻性声明。非历史事实的声明可能被视为前瞻性声明。在不限制前述一般性的情况下，诸如&#34;计划&#34;、&#34;项目&#34;、&#34;潜在&#34;、&#34;寻求&#34;、&#34;可能&#34;、&#34;将&#34;、&#34;期望&#34;、&#34;相信&#34;、&#34;预期&#34;、&#34;打算&#34;、&#34;可以&#34;、&#34;估计&#34;或&#34;继续&#34;等词语旨在识别前瞻性声明。例如，公司在讨论预计收益和发行交割的时间及收益的预期用途时使用了前瞻性声明。读者应注意，某些重要因素可能会影响公司的实际结果，并可能导致这些结果与本新闻稿中可能作出的任何前瞻性声明有实质性差异。可能影响公司结果的因素包括但不限于监管批准、产品需求、市场接受度、竞争产品和价格的影响、产品开发、商业化或技术困难、谈判和贸易的成功或失败、法律、社会和经济风险，以及与现有现金资源充足性相关的风险。其他可能导致公司实际结果与前瞻性声明之间差异的因素包括但不限于公司在 SEC 的备案中讨论的那些风险。读者应注意，实际结果（包括但不限于公司对 Dario™的商业和监管计划的时间和结果的描述）可能与前瞻性声明中所述的结果有显著差异。公司没有义务公开更新任何前瞻性声明，无论是由于新信息、未来事件还是其他原因，除非适用法律要求。</p>
<p><strong>DarioHealth 公司联系方式：</strong></p>
<p>DarioHealth 投资者关系联系人</p>
<p>Michael Lipari</p>
<p>企业发展高级副总裁</p>
<p>irteam@dariohealth.com</p>
<p>+1-201-785-6310</p>
<p>Zoe Harrison</p>
<p>会计与企业发展副总裁</p>
<p>irteam@dariohealth.com</p>
<p>+1-917-856-5505</p>
<p>Logo - https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg</p>
<p>来源 DarioHealth Corp.</p>

IMPP

DRIO

<p>DarioHealth Corp. 宣布进行私募配售，出售 2,713,180 股普通股，价格为每股 6.45 美元，目标筹集约 1,750 万美元。预计交易将在 2025 年 9 月 23 日左右完成，需满足惯例条件。筹集的资金将用于一般企业用途。该发行在证券法下免于注册，并将向 SEC 提交注册声明以供转售。DarioHealth 是一家专注于慢性病管理的数字健康公司</p>

<p>, /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (&#34;Dario&#34; or the &#34;Company&#34;), a leader in the global digital health market, today announced a private placement for the purchase and sale of 2,713,180 shares of common stock (or common stock equivalents in lieu thereof) at a price of $6.45 per share for expected aggregate gross proceeds of approximately $17.5 million, before deducting offering expenses.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO)（&#34;Dario&#34;或&#34;公司&#34;），全球数字健康市场的领导者，今天宣布进行一项私人配售，出售 2,713,180 股普通股（或相应的普通股等价物），每股价格为 6.45 美元，预计总收益约为 1750 万美元，未扣除发行费用。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg"/></p>
<p>The closing of the offering is expected to occur on or about September 23, 2025, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for general corporate purposes.</p>
<div class="lb-trans"><p>此次发行的交割预计将在 2025 年 9 月 23 日左右进行，具体取决于常规交割条件的满足。公司计划将此次发行的净收益用于一般企业用途。</p>
</div><p>The offering is being made in reliance on an exemption from the registration requirement under Section 4(a)(2) of the Securities Act of 1933, as amended (the &#34;Securities Act&#34;), and/or Regulation D promulgated thereunder, and applicable state securities laws. Accordingly, the securities offered in the private placement may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirement of the Securities Act and such applicable state securities laws. The Company has agreed to file a registration statement with the Securities and Exchange Commission (the &#34;SEC&#34;) registering the resale of the shares of common stock sold in the private placement.</p>
<div class="lb-trans"><p>此次发行是基于《1933 年证券法》第 4(a)(2) 条款的注册要求豁免进行的（经修订的&#34;证券法&#34;），和/或根据其下发布的 D 条款，以及适用的州证券法。因此，私人配售中提供的证券不得在美国提供或出售，除非根据有效的注册声明或适用的注册要求豁免。公司已同意向证券交易委员会（&#34;SEC&#34;）提交注册声明，注册私人配售中出售的普通股的转售。</p>
</div><p>This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.</p>
<div class="lb-trans"><p>本新闻稿不构成出售这些证券的要约或购买这些证券的要约邀请，也不应在任何州或其他司法管辖区进行这些证券的出售，除非在任何此类州或其他司法管辖区的证券法下注册或资格之前进行的要约、邀请或出售是合法的。</p>
</div><p><strong>About DarioHealth Corp.</strong></p>
<div class="lb-trans"><p><strong>关于 DarioHealth Corp.</strong></p>
</div><p>DarioHealth Corp. (NASDAQ: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Our platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.</p>
<div class="lb-trans"><p>DarioHealth Corp.（NASDAQ: DRIO）是一家领先的数字健康公司，通过以用户为中心的多慢性病数字治疗平台，彻底改变慢性病患者管理健康的方式。我们的平台和解决方案组合提供个性化和动态的干预措施，基于数据分析和一对一的指导，涵盖糖尿病、高血压、体重管理、肌肉骨骼疼痛和行为健康。</p>
</div><p>Our user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.</p>
<div class="lb-trans"><p>我们的以用户为中心的平台为人们提供持续和定制的健康护理，颠覆了传统的偶发医疗保健方式。这种方法使人们能够全面调整他们的生活方式，以实现可持续的行为改变，从而推动卓越的用户满意度、留存率和结果，使正确的选择变得容易。</p>
</div><p>Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.</p>
<div class="lb-trans"><p>Dario 在全球范围内向健康计划和其他支付方、自保雇主、护理提供者和消费者提供其高度用户评价的解决方案。要了解更多关于 Dario 及其数字健康解决方案的信息，请访问 http://dariohealth.com。</p>
</div><p><strong>Cautionary Note Regarding Forward-Looking Statements</strong> This news release and the statements of representatives and partners of the Company related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as &#34;plan,&#34; &#34;project,&#34; &#34;potential,&#34; &#34;seek,&#34; &#34;may,&#34; &#34;will,&#34; &#34;expect,&#34; &#34;believe,&#34; &#34;anticipate,&#34; &#34;intend,&#34; &#34;could,&#34; &#34;estimate&#34; or &#34;continue&#34; are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the expected proceeds and timing of the closing of the offering and the intended use of proceeds. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the SEC. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.</p>
<div class="lb-trans"><p><strong>关于前瞻性声明的警示说明</strong> 本新闻稿及公司代表和合作伙伴相关的声明包含或可能包含 1995 年《私人证券诉讼改革法》意义上的前瞻性声明。非历史事实的声明可能被视为前瞻性声明。在不限制前述一般性的情况下，诸如&#34;计划&#34;、&#34;项目&#34;、&#34;潜在&#34;、&#34;寻求&#34;、&#34;可能&#34;、&#34;将&#34;、&#34;期望&#34;、&#34;相信&#34;、&#34;预期&#34;、&#34;打算&#34;、&#34;可以&#34;、&#34;估计&#34;或&#34;继续&#34;等词语旨在识别前瞻性声明。例如，公司在讨论预计收益和发行交割的时间及收益的预期用途时使用了前瞻性声明。读者应注意，某些重要因素可能会影响公司的实际结果，并可能导致这些结果与本新闻稿中可能作出的任何前瞻性声明有实质性差异。可能影响公司结果的因素包括但不限于监管批准、产品需求、市场接受度、竞争产品和价格的影响、产品开发、商业化或技术困难、谈判和贸易的成功或失败、法律、社会和经济风险，以及与现有现金资源充足性相关的风险。其他可能导致公司实际结果与前瞻性声明之间差异的因素包括但不限于公司在 SEC 的备案中讨论的那些风险。读者应注意，实际结果（包括但不限于公司对 Dario™的商业和监管计划的时间和结果的描述）可能与前瞻性声明中所述的结果有显著差异。公司没有义务公开更新任何前瞻性声明，无论是由于新信息、未来事件还是其他原因，除非适用法律要求。</p>
</div><p><strong>DarioHealth Corporate Contacts:</strong></p>
<div class="lb-trans"><p><strong>DarioHealth 公司联系方式：</strong></p>
</div><p>DarioHealth Investor Relations Contact</p>
<div class="lb-trans"><p>DarioHealth 投资者关系联系人</p>
</div><p>Michael Lipari</p>
<div class="lb-trans"><p>Michael Lipari</p>
</div><p>SVP Corporate Development</p>
<div class="lb-trans"><p>企业发展高级副总裁</p>
</div><p>irteam@dariohealth.com</p>
<div class="lb-trans"><p>irteam@dariohealth.com</p>
</div><p>+1-201-785-6310</p>
<div class="lb-trans"><p>+1-201-785-6310</p>
</div><p>Zoe Harrison</p>
<div class="lb-trans"><p>Zoe Harrison</p>
</div><p>VP, Accounting and Corporate Development</p>
<div class="lb-trans"><p>会计与企业发展副总裁</p>
</div><p>irteam@dariohealth.com</p>
<div class="lb-trans"><p>irteam@dariohealth.com</p>
</div><p>+1-917-856-5505</p>
<div class="lb-trans"><p>+1-917-856-5505</p>
</div><p>Logo - https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg</p>
<div class="lb-trans"><p>Logo - https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg</p>
</div><p>SOURCE DarioHealth Corp.</p>
<div class="lb-trans"><p>来源 DarioHealth Corp.</p>
</div>

Imperial Petroleum Inc. 宣布对 A 系列优先股派发股息 | IMPP 股票新闻